CCL5 and small cell lung carcinoma: For example, in small cell lung cancer (SCLC), a WEE1 inhibitor induced DNA damage in cancer cells, increasing type I interferons, CCL5 and CXCL10 via activation of the cGAS-STING pathway, enhancing the response to PD-L1 blockade.